Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials

@article{Dobson2015OseltamivirTF,
  title={Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials},
  author={Joanna E Dobson and Richard J Whitley and Stuart J. Pocock and Arnold S. Monto},
  journal={The Lancet},
  year={2015},
  volume={385},
  pages={1729-1737}
}

Figures and Tables from this paper

Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials

It is found that treatment with oseltamivir significantly reduced the duration of illness in those with influenza and lowered the risk of developing otitis media.

Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials

Oseltamivir can effectively alleviate the symptoms of influenza and reduce hospitalization, antibiotic usage, and the risk of otitis media without significantly increasing the rate of adverse drug reactions.

Effectiveness of influenza vaccine in children

It is found that treatment with oseltamivir treatment started within 24 hours of symptom onset provides substantial benefits to children with influenza infection and lowered the risk of developing otitis media.

Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta-analysis of randomized controlled trials

The treatment of influenza with IV peramivir or oral oseltamivIR had similar clinical efficacy and the rate of fever clearance in 24 h and the time to fever resolution were not statistically different between the IV perAMivir and oral oselstam ivir treatments (at different dosages).

Efficacy and Safety of Chinese Patent Medicine Combined With Oseltamivir in Treatment of Children With Influenza: A meta-Analysis

CPMs combined with oseltamivir reduced the duration of symptoms, shortened the time of viral shedding, and reduced the number of ADRs in children with influenza.

Oseltamivir Use for Seasonal and Pandemic Influenza

It is asserted that data on outpatients with relatively mild disease should not form the basis for policies on the management of more severe disease, and randomized controlled trial data may not be able to capture the effect of oseltamivir use among hospitalized patients with severe disease.

Antiviral Medications in Seasonal and Pandemic Influenza.

The benefits of antiviral drugs, particularly neuraminidase inhibitors, outweigh their risks, and physicians should consider the properties of the currently circulating viruses and the patient's individual risk constellation, as directed in clinical treatment recommendations.

Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018

Primary care patients with ILI testing positive for coronavirus (not including SARS-CoV-2) recovered sooner when oseltamivir was added to usual care compared with usual care alone, and may be of relevance to the primary care management of COVID-19.

Efficacy of convalescent plasma for the treatment of severe influenza

The administration of convalescent plasma appears safe but may not reduce the mortality, number of Days in the intensive care unit, or number of days on mechanical ventilation in patients with severe influenza.
...

References

SHOWING 1-10 OF 46 REFERENCES

Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments

The effect on unverified pneumonia in children and for prophylaxis was not significant and there was no significant reduction in risk of unverified bronchitis, otitis media, sinusitis, or any complication classified as serious or that led to study withdrawal.

Antivirals for Treatment of Influenza

Meta-analyses of the few studies providing effects with adjustment for confounders suggest that, in high-risk populations, oral oseltamivir may reduce mortality and pneumonia associated with influenza A and inhaled zanamivIR may provide a net benefit over no treatment of influenza.

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

Oseltamivir was associated with lower [corrected] symptom scores, less viral shedding, and improved health, activity, and sleep quality, and was well tolerated in the treatment of natural influenza infection in adults.

Oral oseltamivir treatment of influenza in children

Oseltamivir treatment did not affect the influenza-specific antibody response and is an efficacious and well-tolerated therapy for influenza in children when given within 48 h of onset of illness.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

The remaining evidence suggests oseltamivir did not reduce influenza related lower respiratory tract complications and neuraminidase inhibitors have modest effectiveness against the symptoms of influenza in otherwise healthy adults.

Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza

The data suggest that oral oseltamivir treatment reduces the duration and severity of acute influenza in healthy adults and may decrease the incidence of secondary complications.

A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China.

Oseltamivir was effective and well tolerated as treatment of early naturally acquired influenza in the intent-to-treat infected population and for the ITT population, similar results were observed.

Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants.

  • M. LipsitchM. Hernán
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2013
A meta-analysis of randomized controlled trials found that oseltamivir reduced the risk of antibiotic-treated lower respiratory tract complications by 28% (95% confidence interval], 11%– 42%) in outpatients and by 37% inOutpatients with laboratory-confirmed influenza infections.

Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.

Respiratory complications or worsening of symptoms leading to antibiotic use occurred in about 17% of adolescents or adults with influenza infection, and early treatment with zanamivir reduced the number of these antibiotic prescriptions.